SciSparc Announces Initiation of Patient Recruitment for its

The clinical trial for SCI-210 will be conducted in Israel, after which the company aims to move forward with the commercialization process of SCI-210 first in the Israeli market

Related Keywords

Israel , Israeli , Oz Adler , Scisparc Palmitoylethanolamide , Nasdaq , Scisparc Ltd , Company Or Scisparc , National Autism Research Center , Soroka Medical Center , Exchange Commission , Chief Executive Officer , Aberrant Behavior Checklist Community , Clinical Global Impressions Improvement , Tourette Syndrome , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Region ,